Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. Issue 4 (10th November 2020)

• Record Type: Journal Article
• Authors: Nanzer, Alexandra M.; Dhariwal, Jaideep; Kavanagh, Joanne; Hearn, Andrew; Fernandes, Mariana; Thomson, Louise; Roxas, Cris; Green, Linda; D'Ancona, Grainne; Agarwal, Sangita; Kent, Brian D.; Jackson, David J.
• Is Part Of: ERJ open research. Volume 6:Issue 4(2020)
• Publication Date: 2020-11-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00451-2020
• Languages: English
• ISSNs: 2312-0541

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterised by asthma, chronic rhinosinusitis and blood eosinophilia, which may be accompanied by neurological, cardiac, cutaneous and renal involvement [1]. Oral corticosteroids (OCS) are the most frequently used drugs to control eosinophilic inflammation and symptoms. Persistent symptoms or relapses are common, however, and many patients are at risk of developing long-term complications from systemic steroid therapy [2]. The ability of other immunosuppressant agents to achieve consistent disease control or to reduce maintenance OCS (mOCS) requirements appears to be limited [3]. Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf